New York, United States
Lodo Therapeutics Corporation, founded in 2015 and headquartered in the United States, is at the forefront of revolutionizing drug discovery. The company operates with the bold vision encapsulated in its slogan: "Clusters to cures: tapping evolution’s diversity to reinvent drug discovery." Lodo focuses on discovering and developing therapeutics for "undruggable" targets, which present high unmet medical needs.
Lodo leverages a proprietary platform that utilizes advancements in next-generation sequencing, artificial intelligence, machine learning, and synthetic biology to mine microbial DNA for drug-like molecules. These molecules boast remarkable structural diversity and biological relevance sculpted by a billion years of evolution, making them promising candidates for drug development. The initial focus is within oncology, although the company is actively expanding partnerships across various indications.
The company's strategic development was endorsed by a significant Acquisition investment from investors including Merge on 01 May 2021. Positioned within Biotechnology, Health Care, and Pharmaceuticals, Lodo's promising technology represents an attractive opportunity for investors seeking innovation in these sectors.
